BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 6, 2026
See today's BioWorld
Home
» Newlink Adds $42.5M in Public Offering for Immunotherapies
To read the full story,
subscribe
or
sign in
.
Newlink Adds $42.5M in Public Offering for Immunotherapies
Jan. 31, 2013
By
Catherine Shaffer
NewLink Genetics Corp.'s HyperAcute technology will get a boost from a public offering of 4 million shares of common stock in the company priced at $11.40 per share, or net proceeds of $42.5 million.
BioWorld